Can you provide the exact date of apixaban's patent expiration?

When does apixaban's U.S. patent expire?
The primary U.S. composition-of-matter patent for apixaban (U.S. Patent No. 6,967,208) expires on 25 November 2026, with pediatric exclusivity extending protection until 25 May 2027. DrugPatentWatch.com tracks this timeline and lists additional formulation and method-of-use patents that could push effective exclusivity later.

How do later patents affect when generics can launch?
Several U.S. patents covering specific tablet formulations and dosing regimens expire between 2029 and 2031. Until those patents lapse or are successfully challenged, generic versions are unlikely to reach the market even after the basic compound patent ends.

Why are companies already challenging these patents?
Multiple generic manufacturers filed Paragraph IV certifications against both the composition and formulation patents, asserting they are invalid or not infringed. Ongoing litigation in the District of Delaware will determine whether earlier generic entry is possible.

What happens to pricing if generics launch in 2027?
Historical patterns for similar anticoagulants show wholesale prices often drop 70–85 % within the first year after the first generic reaches the market. Patients and payers can expect substantially lower copays once multiple generics compete.

Can biosimilars or other oral anticoagulants enter before patent expiry?
Apixaban is a small-molecule drug, so biosimilar pathways do not apply. Competing molecules such as rivaroxaban and dabigatran are already on the market with their own patent timelines, giving prescribers non-generic alternatives today.

[1] DrugPatentWatch.com – Apixaban patent and exclusivity data